Gilead Sciences, Inc.
333 Lakeside Drive
Foster City
California
94404
United States
Tel: 800-GILEAD-5 or 650-574-3000
Fax: 650-522-5800
Website: http://www.gilead.com/
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need.The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
YEAR FOUNDED:
1987
LEADERSHIP:
CEO: John F. Milligan, PhD
Chief Scientific Officer: Norbert W. Bischofberger, PhD
CFO: Robin L. Washington
COO: Kevin Young
CLINICAL TRIAL:
Please click here for clinical trial information.
1421 articles with Gilead Sciences, Inc.
-
Gilead Subsidiary to Launch Authorized Generics of Epclusa® (Sofosbuvir/Velpatasvir) and Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C
9/24/2018
List Price of Authorized Generics to Reflect Discounts in the System Today
-
Following AbbVie Lawsuit, Government Scrutinizes Industry-Provided Drug Educational Support Services
9/21/2018
A federal investigation is underway into whether or not the nursing and other medical services provided by some pharmaceutical companies to doctor’s offices actually violate the law due to serving an illegal commercial service. -
San Diego-based Viking Therapeutics announced positive top-line data from a 12-week Phase II clinical trial of VK2809 in non-alcoholic fatty liver disease (NAFLD) and elevated low-density lipoprotein cholesterol (LDL-C).
-
Accord secures victory in English High Court as Gilead’s SPC for Truvada held invalid
9/18/2018
On the morning of 18 September 2018, the English High Court handed down its judgment concerning Gilead’s SPC (Supplementary Protection Certificate) for its antiretroviral product Truvada.
-
Identification of synthetic, macrocyclic, orally bioavailable cyclophilin inhibitors with potent HCV activity, published in The Journal of Medicinal Chemistry
9/17/2018
A paper entitled ‘Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle’ by authors from Selcia, Cypralis and Gilead has been selected as a featured article by the editors of The Journal of Medicinal Chemistry.
-
The Morgan Stanley Global Healthcare Conference ran from September 12 through 14, with numerous biopharma companies making presentations, updating their operations and pipeline activities. Here’s a look a few of the highlights.
-
Belgium-based Galapagos NV snagged $300 million following its U.S. public offering of new ordinary shares in the form of American Depositary Shares.
-
Gilead Sciences and Precision BioSciences Announce Collaboration to Develop Therapies Against Hepatitis B Virus Using ARCUS Genome Editing
9/12/2018
Gilead Sciences and Precision BioSciences announced today that the companies have entered into a strategic collaboration to develop therapies targeting the in vivo elimination of hepatitis B virus (HBV) with Precision’s proprietary genome editing platform, ARCUS.
-
Gilead Sciences had a lot of news lately. First off, Gilead and Belgium-based Galapagos NV announced results from their FINCH 2 Phase III clinical trial of filgotinib in adults with moderately-to-severely active rheumatoid arthritis.
-
Gilead and Galapagos Announce TORTUGA Phase 2 Study of Filgotinib in Ankylosing Spondylitis Achieves Primary Endpoint
9/6/2018
Gilead Sciences, Inc.and Galapagos NV today announced that the randomized, placebo-controlled Phase 2 TORTUGA study of filgotinib, an investigational, selective JAK1 inhibitor, achieved its primary efficacy endpoint in adults with moderately to severely active ankylosing spondylitis (AS).
-
With Phase II Win for Ankylosing Spondylitis, Gilead and Galapagos' Filgotinib Inches Toward Appr...
9/6/2018
Gilead Sciences and its partner Galapagos NV announced results from its Phase II TORTUGA clinical trial of filgotinib, a selective JAK1 inhibitor, in adults with moderately to severely active ankylosing spondylitis (AS). -
A number of companies are making the transition from the third quarter to the fourth quarter with licensing deals to bolster their pipelines. Here’s a look at just a few of them.
-
Movers and Shakers for Sept. 4
9/4/2018
Biopharm companies closed out August with a plethora of changes to executive and senior leadership positions. Let's take a look. -
Nearly two months ahead of the planned PDUFA date, the U.S. Food and Drug Administration approved two new HIV-1 treatments developed by Merck. The FDA gave the go ahead for Delstrigo, a once-per day triple combination treatment and Pifeltro, a new non-nucleoside reverse transcriptase inhibitor.
-
Gilead Sciences announced the appointment of Laura Hamill as executive vice president, Worldwide Commercial Operations, and member of the company’s senior leadership team.
-
Gilead Sciences Appoints Laura Hamill as Executive Vice President, Worldwide Commercial Operations
8/28/2018
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Laura Hamill will join the company as Executive Vice President, Worldwide Commercial Operations, and will become a member of Gilead’s senior leadership team.
-
The United Kingdom’s government-funded health service isn’t being so nice to Gilead Science’s CAR-T blood cancer treatment Yescarta. The country’s National Institute for Health and Care Excellence (NICE) said the therapy is too expensive for the agency to justify.
-
Yescarta® (Axicabtagene Ciloleucel) Receives European Marketing Authorization for the Treatment of Relapsed or Refractory DLBCL and PMBCL, After Two or More Lines of Systemic Therapy
8/27/2018
New Option for Adult Patients in Europe as Axicabtagene Ciloleucel Becomes the First CAR T to Receive European Approval for Two Types of Aggressive Non-Hodgkin Lymphoma
-
Novartis’s Breast Cancer Drug Looks Promising in Phase III Trial, Despite Category’s Troubling Hi...
8/23/2018
Novartis announced that its BYL719 (alpelisib) met the primary endpoint of progression-free survival (PFS) in its Phase III SOLAR-1 trial. The drug is an alpha-specific PI3K inhibitor, a category of cancer drugs that has a troubling history of adverse events. -
By many standards, and certainly by the way the media covers it and industry promotes it, immuno-oncology therapies using CAR-T are revolutionizing cancer treatments. But what if, as the saying goes, they threw a revolution and nobody came? Or more precisely, what if they threw a revolution and n...